We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+3.47%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$504B
AUM Growth
+$5.92B
Cap. Flow
-$3.19B
Cap. Flow %
-0.63%
Top 10 Hldgs %
16.49%
Holding
2,620
New
96
Increased
950
Reduced
1,023
Closed
72

Top Buys

Rank Stock Value
1
WFC icon
Wells Fargo
WFC
+$1.31B
2
HD icon
Home Depot
HD
+$1.07B
3
BABA icon
Alibaba
BABA
+$1.06B
4
YUM icon
Yum! Brands
YUM
+$887M
5
HON icon
Honeywell
HON
+$860M

Top Sells

Rank Stock Value
1
N
Netsuite Inc
N
+$1.59B
2
NXPI icon
NXP Semiconductors
NXPI
+$1.33B
3
DHR icon
Danaher
DHR
+$1.13B
4
HBI
Hanesbrands
HBI
+$1.06B
5
TMO icon
Thermo Fisher Scientific
TMO
+$845M

Sector Composition

Rank Sector Weight
1 Financials 16.86%
2 Healthcare 16.8%
3 Consumer Discretionary 15.02%
4 Technology 13.29%
5 Industrials 9.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IMGN
2501
DELISTED
Immunogen Inc
IMGN
$56K ﹤0.01%
27,600
-46,600
-63% -$93.6K
SQBG
2502
DELISTED
Sequential Brands Group, Inc.
SQBG
$55K ﹤0.01%
293
BDSI
2503
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$55K ﹤0.01%
31,500
CARM
2504
DELISTED
Carisma Therapeutics
CARM
$54K ﹤0.01%
1,410
GNRT
2505
DELISTED
Gener8 Maritime, Inc.
GNRT
$53K ﹤0.01%
11,754
APVO icon
2506
Aptevo Therapeutics
APVO
$5.42M
0
SUMR
2507
DELISTED
Summer Infant, Inc.
SUMR
$50K ﹤0.01%
2,722
CAW
2508
DELISTED
CCA Industries, Inc.
CAW
$50K ﹤0.01%
19,247
QUMU
2509
DELISTED
Qumu Corp.
QUMU
$49K ﹤0.01%
20,750
GNSS icon
2510
Genasys
GNSS
$76.5M
$47K ﹤0.01%
27,759
STRR
2511
Star Equity Holdings
STRR
$40.1M
$46K ﹤0.01%
3,391
TIK
2512
DELISTED
Tel-Instrument Electronics Corp.
TIK
$46K ﹤0.01%
10,455
HHS icon
2513
Harte-Hanks
HHS
$18.6M
$45K ﹤0.01%
2,975
NAVB
2514
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$44K ﹤0.01%
3,500
ASTC icon
2515
Astrotech Corp
ASTC
$18M
$43K ﹤0.01%
193
+8
+4% +$1.95K
FPP
2516
DELISTED
FieldPoint Petroleum Corporation
FPP
$43K ﹤0.01%
59,200
RTK
2517
DELISTED
Rentech, Inc.
RTK
$42K ﹤0.01%
16,950
OCC icon
2518
Optical Cable Corp
OCC
$149M
$41K ﹤0.01%
12,869
ARWR icon
2519
Arrowhead Research
ARWR
$12.5B
$40K ﹤0.01%
25,567
LPTH icon
2520
Lightpath Technologies
LPTH
$873M
$40K ﹤0.01%
26,100
NBSE
2521
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$40K ﹤0.01%
67
CRDF icon
2522
Cardiff Oncology
CRDF
$79.4M
$37K ﹤0.01%
246
-1
-0.4% -$234
CMLS
2523
DELISTED
Cumulus Media Inc. Class A Common Stock
CMLS
$37K ﹤0.01%
36,148
-3
-0% -$4
CEMP
2524
DELISTED
Cempra, Inc.
CEMP
$30K ﹤0.01%
10,814
-58,116
-84% -$705K
BIOL
2525
DELISTED
Biolase, Inc.
BIOL
$24K ﹤0.01%
1

Similar funds

T. Rowe Price Associates's Q4 2016 Portfolio in Review

As of Q4 2016, T. Rowe Price Associates held 2,620 positions worth $504B, up 1.2% from $498B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

T. Rowe Price Associates's Q4 2016 filing shows 96 new, 950 increased, 1,023 reduced and 72 closed positions. Its largest new stake was Adient: 10,357,941 shares worth $607M. The largest sale was Netsuite Inc, an estimated $1.59B.

By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2016 buy was Adient: 10,357,941 shares worth $607M.
  • T. Rowe Price Associates added most to Wells Fargo in Q4 2016, an estimated $1.31B increase.
  • T. Rowe Price Associates's biggest Q4 2016 reduction was NXP Semiconductors, cutting an estimated $1.33B.
  • T. Rowe Price Associates fully exited Netsuite Inc in Q4 2016, selling an estimated $1.59B.
  • T. Rowe Price Associates's ten largest holdings make up 16% of its $504B portfolio in Q4 2016.
  • T. Rowe Price Associates opened 96 new positions and closed 72 in Q4 2016.
  • T. Rowe Price Associates's portfolio value rose 1.2% quarter-over-quarter to $504B.

Based on T. Rowe Price Associates's 13F filing for Q4 2016, filed 14 Feb 2017.